PIMAGEDINE

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII SCQ4EZQ113
EPA CompTox DTXSID5040964

Structure

InChI Key HAMNKKUPIHEESI-UHFFFAOYSA-N
Smiles N=C(N)NN
InChI
InChI=1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)

Physicochemical Descriptors

Property Name Value
Molecular Formula CH6N4
Molecular Weight 74.09
AlogP -1.87
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 0.0
Polar Surface Area 90.42
Molecular species BASE
Aromatic Rings 0.0
Heavy Atoms 5.0
Assay Description Organism Bioactivity Reference
Tested for ability to competitively inhibit hog kidney diamine oxidase (DAO) in a spectrometric assay Sus scrofa 140.0 nM
Tested for the inhibition of NO production in RAW 264.7 cells Mus musculus 79.0 %
Inhibition of LPS-induced NO production in RAW 264.7 cells at 0.1 uM after 20 hrs Mus musculus 85.0 %
Inhibition of advanced glycation end product formation at 1 mM after 7 days by fluorescence assay None 60.5 %
Inhibition of LPS-induced nitric oxide synthesis in mouse RAW264.7 macrophages after 18 hrs of LPS challenge measured after 18 hrs by ELISA relative to LPS-treated control Mus musculus 78.8 %
Inhibition of advanced glycation end product formation assessed as CML level at 1 mM after 7 days in 0.1 M phosphate buffer at pH 7.4 by ELISA relative to control None 76.0 %
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production Mus musculus 3.4 ug.mL-1
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO release Mus musculus 3.3 ug.mL-1
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release after 24 hrs Mus musculus 50.0 nM
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of lipopolysaccharide/interferon-gamma induced PGE2 production at 1 uM by EIA Mus musculus 8.0 %
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of lipopolysaccharide/interferon-gamma induced PGE2 production at 3 uM after 18 hrs Mus musculus 21.0 %
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of lipopolysaccharide/interferon-gamma induced PGE2 production at 10 uM after 18 hrs Mus musculus 42.0 %
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 100 uM after 24 hrs by Griess reaction relative to control Mus musculus 86.0 %
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 50 uM after 24 hrs by Griess reaction relative to control Mus musculus 74.9 %
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 25 uM after 24 hrs by Griess reaction relative to control Mus musculus 52.5 %
Antiglycation activity assessed as inhibition of advanced glycation end product formation at 200 uM None 79.67 %
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins before LPS challenge measured 24 hrs after LPS challenge by Griess reaction method Mus musculus 200.0 nM
Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 100 uM after 20 hrs by Griess method Mus musculus 74.0 %
Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 50 uM pretreated for 20 mins before LPS challenge measured after 18 hrs post LPS challenge by spectrophotometry Mus musculus 71.0 %
Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 25 uM pretreated for 20 mins before LPS challenge measured after 18 hrs post LPS challenge by spectrophotometry Mus musculus 56.0 %
Inhibition of iNOS-mediated NO production in IL-1beta/IFNgamma-stimulated rat RINmF cells at 39 to 78 uM by Griess reaction Rattus norvegicus 10.0 %
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 25 uM after 18 hrs by Griess method relative to control Mus musculus 83.8 %
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite production at 50 uM after 22 hrs by Griess method relative to LPS-treated control Mus musculus 70.2 %
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method Mus musculus 230.0 nM
Inhibition of vesperlysine-type advanced glycation end products formation using bovine serum albumin after 24 hrs by microtiter plate assay None 700.0 ug.mL-1
Inhibition of pentosidine-type advanced glycation end products formation using bovine serum albumin after 24 hrs by microtiter plate assay None 150.0 ug.mL-1
Anti-glycation activity assessed as inhibition of AGE formation by measuring decrease in glycated BSA protein level at 1000 uM incubated for 24 hrs in presence of glucose by fluorescence based assay relative to control None 57.8 %
Anti-glycation activity assessed as inhibition of AGE formation by measuring decrease in glycated BSA protein level at 100 uM incubated for 24 hrs in presence of glucose by fluorescence based assay relative to control None 6.0 %
Inhibition of AGE formation assessed as reduction in reduction in bovin serum albumin glycation at 1 mM incubated for 24 hrs in presence of glucose, Cu2+ by spectrophotometric analysis relative to control None -18.6 %
Inhibition of AGE formation assessed as reduction in bovin serum albumin glycation at 1 mM incubated for 24 hrs in presence of glucose by spectrophotometric analysis relative to control None 57.8 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 25.83 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 12.23 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.03 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.02 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.02 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.03 %

Cross References

Resources Reference
ChEBI 40618
ChEMBL CHEMBL225304
DrugBank DB05383
FDA SRS SCQ4EZQ113
Guide to Pharmacology 5135
PDB AGU
PubChem 2146
SureChEMBL SCHEMBL15307
ZINC ZINC000008034829
CONTENTS